Phase I/II trial: DT2216, a BCL‑xL degrader, combined with irinotecan for refractory pediatric cancers

This phase I/II trial by the Children’s Oncology Group evaluates the safety, tolerability, and preliminary efficacy of DT2216 with irinotecan in children, adolescents, and young adults with relapsed or refractory solid tumors and fibrolamellar carcinoma (with DNAJB1:PRKACA fusion). The study explores a first-in-human combination aimed at targeting tumor cell survival.